

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61F 2/02, A61K 9/14, 9/20, 9/48, A61M 31/00		A1	(11) International Publication Number: WO 94/21195 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/US94/02854		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 March 1994 (15.03.94)		Published <i>With international search report.</i>	
(30) Priority Data: 08/033,310 15 March 1993 (15.03.93) US			
(71) Applicant (for all designated States except US): GENSIA, INC. [US/US]; 9360 Towne Centre Drive, San Diego, CA 92121 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): DOWNEY, James, M. [US/US]; 1220 Anchor Drive, Mobile, AL 36693 (US). MULLANE, Kevin, M. [GB/US]; 13814 Boquita Drive, Del Mar, CA 92014 (US).			
(74) Agents: TEKANIC, Jeffrey, D. et al.; Lyon & Lyon, 611 West Sixth Street, 34th floor, Los Angeles, CA 90017 (US).			

(54) Title: METHODS FOR PROTECTING TISSUES AND ORGANS FROM ISCHEMIC DAMAGE



TREATMENT WITH:

- 1). GLOBAL ISCHEMIA
- 2). ADO (10 uM)
- 3). APNEA (50 nM)

(57) Abstract

Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptor.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONMethods For Protecting Tissues
And Organs From Ischemic DamageCross-Reference To Related Applications

This application is a continuation-in-part of serial number No. 08/033,310, filed March 15, 1993; the disclosures of this application are incorporated herein.

5 Technical Field

The present invention relates to methods of administering compounds to tissue to protect organs, such as the heart, the brain or the kidney, from ischemic injury, infarction, bradycardia, fibrillation, stunning, 10 A-V conduction delays and other disorders. Specifically, the compounds administered to protect the organ selectively activate A3 adenosine receptors.

Background Of The Invention

In the United States, diseases caused by ischemia 15 such as heart disease continue to be a major health problem. One type of disease results in the interruption of nutritional blood flow to the heart, brain or kidney tissue from blockage of a major coronary artery. Although blood flow can often be restored with thrombolytic 20 treatment, it is usually administered too late to prevent irreversible damage. Moreover, the restoration of blood flow also can result in reperfusion injury, where the ultimate degree of tissue damage is greater than would be expected, if the reintroduction of blood and nutrients 25 arrested all damage.

For example, of the 1.5 million people each year who suffer myocardial ischemia (the interruption of coronary blood flow), approximately 700,000 who survive myocardial ischemia that have myocardial infarction (dead heart 30 tissue). For those people who survive with a myocardial

infarction, the ischemic damage can form the basis for cardiac arrhythmias, such as bradycardia (abnormally slow heart beats), tachycardia (abnormally fast heart beats) and fibrillation (disorganized heart rhythms wherein the heart quivers rather than beats). About 400,000 people die each year from cardiac arrhythmias.

Protection against infarction has become a long-term goal of cardiology, because infarcted heart muscle cannot be regenerated and is a deficit that the patient must contend with for the remainder of his or her life; therefore a therapy which would cause the heart to better tolerate a period of ischemia is greatly desired. Such a therapy could increase the possibility that timely restoration of the coronary blood flow would salvage myocardial tissue. Such a therapy could also reduce the damage in an area of permanent occlusion. Although many drugs have been proposed to protect the ischemic myocardium, such as beta-blockers, free-radical scavengers, and calcium antagonists, virtually all have performed poorly in whole animal models. Therefore, methods and compounds are needed to both prevent and reduce the damage from ischemic events.

Interestingly, ischemia can be protective as well as injurious and methods for ischemic preconditioning of organs, such as the heart, brain or kidney have been described recently. Ischemic preconditioning refers to a phenomenon whereby a brief period of ischemia renders the myocardium very resistant to infarction from a subsequent ischemic insult. [Downey, J.M.: Ischemic preconditioning. 30 Nature's Own Cardioprotective Intervention. TCM 1992; 2:170-176.] The use of this ischemic preconditioning technique consists, in the case of the heart, of interrupting the blood flow through the coronary artery to the heart muscle for five minutes by coronary branch occlusion, followed by reperfusion, or restoring blood flow to the heart, for ten minutes. If the coronary blood flow is restored after five minutes of ischemia, not only will the

heart fully recover with no cell death, but the heart will become very resistant to infarction from any subsequent ischemic insult. [See e.g., Liu, Y. and Downey, J.M. Ischemic preconditioning protects against infarction in 5 rat heart. *Am J Physiol* 1992; 263:H1107-H1112.] Although ischemic preconditioning appears to be universally accepted as a powerful cardioprotectant, it is obviously not the type of intervention that could be administered to the acute myocardial infarction patient.

10 While the exact mechanism for ischemic preconditioning is not known, as a result of testing in various animal models, ischemic preconditioning appears to be mediated by adenosine which is released during the short ischemic event and populates the adenosine receptors. 15 [Liu, G.S., et al.: Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. *Circulation* 1991; 84:350-356.] Previously, two types of adenosine receptors have been described, specifically the A1 and A2 adenosine receptors. 20 [Olsson, R.A., Pearson, J. D.: Cardiovascular purinoreceptors. *Physiol Rev* 1990; 70:761-845.] In myocardium, stimulation of A1 adenosine receptors is associated with bradycardia and constricts blood vessels, while A2 receptors mediate coronary vasodilation and inhibit 25 neutrophil activation. Virtually all previous work has indicated that only the A1 adenosine receptor is involved in initiating the preconditioning protection. [See e.g., Downey, J.M., et al., Adenosine and the anti-infarct effects of preconditioning. *Cardiovascular Research* 1993; 30 27:3-8.] The A2 adenosine receptor has not been implicated.

As a prospective preconditioning compound, adenosine has been investigated, but the problems associated with administering adenosine outweigh the myocardial benefits. 35 While adenosine does possess ischemic protective abilities, it can only be administered by selective infusion into the coronary artery, as an intravenous

SUBSTITUTE SHEET (RULE 26)

injection would cause too much hypotension at doses required for ischemic preconditioning. [Downey, J.M., et al., Adenosine and the anti-infarct effects of preconditioning. Cardiovascular Research 1993; 27:3-8.] Also, 5 increasing evidence exists that adenosine is a mediator of the sensation of anginal pain. Furthermore, adenosine is extremely labile in blood with a half-life of only seconds. [Moser, G.H., et al., Turnover of adenosine in plasma of human and dog. Am J Physiol 1989; 256:C799-10 C806.] Thus, adenosine is an unlikely candidate for medical treatment of acute myocardial infarction or as a infarction prevention drug.

Adenosine analogues which are capable of selectively activating the A1 adenosine receptor (A1-selective 15 agonists) also have been investigated. Although adenosine analogues which are the A1-selective agonists, such as N⁶-(phenyl-2R-isopropyl)-adenosine (R-PIA) and 2-chloro-N⁶-cyclopentyladenosine (CCPA), have been shown to provide beneficial ischemic preconditioning effects when 20 intercoronarily infused before an ischemic insult, undesirable side effects from activation of the A1 adenosine receptor, e.g. hypotension, A-V conduction delays, bradycardia, narcosis, bronchial spasm, negative inotropic activity and renal vasoconstriction, may present 25 an insurmountable obstacle to achieving a practical therapy based on parenteral administration of A1-selective agonists. [See e.g., Thornton, J.D., et al., Intravenous Pretreatment With A1-Selective Adenosine Analogues Protects the Heart Against Infarction. Circulation, 1992; 30 85:659-665.]

Recently, a third adenosine receptor, the A3, has been characterized. [Zhou, Q.Y., et al., Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor. Proc Natl Acad Sci 1992; 89:7432-35 7436.] It is reported that the A3 adenosine receptor cloned from rat brain, designated R226, shares high sequence identity with the two previously identified

adenosine receptors. R226 has been reported to bind the non-selective adenosine agonists N-ethyladenosine 5'-uronic acid (NECA), and the A1-selective agonist N⁶-2-(4-amino-3-iodophenyl)-ethyladenosine (APNEA), but not to bind the A1-selective antagonists 1,3 dipropyl-8-cyclopentylxanthine (DPCPX) and 8-{4-[(2-aminoethyl)amino]-carbonyl}methyl)oxyl-phenyl}-1,3-dipropylxanthine (XAC). Nothing has been currently reported about its physiological role.

10 Firestein, et al., U. S. Patent application serial 08/070,689 describes DNA encoding Human adenosine A3 receptor, isolated human A3 receptor, cells expressing the same and uses thereof.

15 Andrew J. van Bergen, et al., *Abstracts of Papers*, 206th National Meeting of the American Chemical Society, Chicago, IL, 1993, MEDI 217, proposed a preliminary structure activity relationship for some A3 receptor agents. Further, Kenneth A. Jacobson, et al., *Abstracts of Papers*, 207th National Meeting of the American Chemical 20 Society, San Diego, CA, 1994, MEDI 244, reported N6-benzyladenosine 5'-uronamides as selective agonists for rat brain A3 receptor.

25 Christopher Salavatore, et al., Proc. Natl. Acad. Sci. USA 90 (1993) reported the binding constants for several agents to the human A3 adenosine receptor.

Joel Link, et al., Mol. Pharmacol. 44:524-532 (1993) also proposed a preliminary structure activity relationship for binding of some A3 receptor agents to recombinant sheep A3 adenosine receptor.

30 Summary Of The Invention

The present invention relates to the discovery that the A3 adenosine receptor is the mediator of ischemic preconditioning, and selective activation of the A3 adenosine receptor renders organs such as the myocardium 35 resistant to subsequent ischemic insults without negative side effects such as heart block or hypotension. Ischemic

preconditioning can be mimicked by administering compounds which selectively activate the A3 adenosine receptor.

Thus, one aspect of the present invention relates to methods for preconditioning organs such as the heart, 5 brain or kidney by administering a molecule which is an A3 adenosine receptor-selective agonist. This method has the advantage of providing protection to myocardial tissue in the event a subsequent ischemic insult occurs without causing the unwanted side effects inherent to activation 10 of the A1 adenosine receptor. Therefore it is an aspect of the present invention to provide protection without causing unwanted side effects such as heart block, bradycardia or significant hypotension.

In another aspect, the present invention relates to 15 a method for selectively activating the A3 adenosine receptor by administering an agonist to the A3 adenosine receptor together with an antagonist to the A1 adenosine receptor, thereby ensuring the prevention of any unwanted A1 stimulation side effects.

20 In another aspect, the present invention relates to a method for selectively activating the A3 adenosine receptor by administering an agonist to the A3 adenosine receptor together with a molecule that is an antagonist to the A1 adenosine receptor and with an antagonist to the A2 25 adenosine receptor. This method does not require the A3 agonist to be specific to A3 only and also ensures against provoking any unwanted A2 stimulation side effects.

In one preferred embodiment, the present invention 30 relates to methods of administering compounds which selectively stimulate the A3 adenosine receptor and thereby prevent ischemic injury during surgery. Such compounds may be administered orally or preferably intravenously prior and/or during surgery.

35 In another preferred embodiment, the present invention relates to methods for administering compounds which selectively stimulate the A3 adenosine receptor to prevent further ischemic injury after acute myocardial

SUBSTITUTE SHEET (RULE 26)

infarction has occurred. Such compounds could be administered orally or preferably intravenously. Alternatively such compounds might be orally administered in a prophylactic manner to high-risk patients, i.e., those at high 5 risk of heart attack due, for example, to previous attacks or to atherosclerosis or to pending surgery.

The invention further involves the identification of patients in need of treatment who are at risk for adverse clinical outcomes, including adverse cardiovascular and 10 adverse cerebrovascular events. Risk factors for those patients undergoing cardiac surgery include elevated age (for example, above 65 years of age); emergency or urgent surgery which may be complicated by unstable angina; failed percutaneous transluminal coronary angioplasty; 15 decreased left ventricular function (as determined by an ejection fraction of less than 40%); chronic or acute renal failure; dysrhythmia (under treatment); or myocardial infarction within the past several years. See, e.g., Manango, Anesthesiology 72:153-84 (1990). Risk 20 factors for those patients undergoing non-cardiac surgery include advanced age (for example 65-70 years of age); atherosclerotic heart disease, i.e., coronary artery disease, as evidenced by peripheral vascular disease or carotid artery disease; diabetes; renal failure; heart 25 failure under therapy; left ventricular hypertrophy and hypertension; hypertension for over five years; emergency or urgent surgery; myocardial infarction within six months to one year prior to surgery; angina; arrhythmia or hypercholesterolemia. The invention also includes 30 identification of patients in need of prophylactic administration of an A3 agonist because of a chronic, genetic or similar condition or due to angina, transient ischemia attack, evolving or recent myocardial infarction, or evolving or recent stroke.

35 In another preferred embodiment, the present invention relates to methods for administering compounds which selectively stimulate the A3 adenosine receptor as

SUBSTITUTE SHEET (RULE 26)

a program for continual preconditioning. This method would provide the advantage of maintaining the heart or other organ in a preconditioned state indefinitely and would be appropriate for patients who are at high risk of 5 myocardial infarction, thereby allowing them to better tolerate an ischemic event. Preferably, such treatment would involve the intermittent administration of the agonist, as continual administration of a receptor agonist may result in the undesired side effects of down 10 regulation of the receptor or of tolerance.

Another preferred embodiment of the present invention is the use of a specific adenosine A3 agonist. The specificity of said agonist is defined by having a ratio of A3 receptor affinity versus A1 and/or A2 receptor 15 affinity of at least about 10 to 1 and more preferably about 100 to 1.

Other aspects, advantages and embodiments of the invention will be apparent from the following description of the preferred embodiments, the figures and from the 20 claims.

Brief Description Of The Drawings

Figure 1 is a depiction of the experimental protocol used to screen compounds for preconditioning the heart.

Figure 2 is a graphical depiction of the comparison 25 of the protective effects of ischemic, adenosine and APNEA preconditioning on the heart.

Figure 3 is a graphical depiction of the comparison of the protective effects of ischemic, adenosine and APNEA preconditioning on the heart when 8-SPT is administered as 30 an A1 adenosine receptor-selective antagonist.

Figure 4 is a graphical depiction of the comparison of the protective effects of ischemic, adenosine and APNEA preconditioning on the heart when DPCPX is administered as an A1 adenosine receptor-selective antagonist.

35 Figure 5 is a graphical depiction of the comparison of the protective effects of preconditioning, precondi-

tioning coupled with administration of an A1 antagonist (DPCPX), the administration of the A3 agonist APNEA and the coadministration of the adenosine A3 agonist APNEA and the A1 antagonist DPCPX.

5 Detailed Description Of The Preferred Embodiment

The present invention provides novel methods for preconditioning organs such as the heart, brain or kidney to prevent or reduce tissue damage, if the organ experiences an ischemic insult. These methods are based 10 upon the recognition that selective stimulation or activation of the A3 adenosine receptor provides beneficial preconditioning effects which prevent or reduce damage to tissue from an ischemic insult. Selective stimulation of the A3 adenosine receptor also will 15 maximize desired protective benefits, while minimizing unwanted side effects from the stimulation of the A1 and A2 adenosine receptors, such as heart block or hypotension. Therefore, methods and compounds are described and claimed which will promote selective 20 stimulation of the A3 adenosine receptor.

The term "preconditioning" refers to the treatment of an organ before, during or after an ischemic event. Although the term encompasses the prophylactic treatment of an organ considered at risk of such an event, it is not 25 intended to limit treatment only in advance of the event.

The term "receptor" refers to a macromolecule capable of recognizing and selectively binding with a ligand, and which after binding the ligand, is capable of generating a physical or chemical signal that initiates the chain of 30 events leading to the physiological response. [Blecher, M., et al., Receptors and Human Disease. Williams & Wilkins, Baltimore, 1981, Chapter 1.] Adenosine receptors are proteins found in animals and humans which can bind the ligand, adenosine, causing a physiological response. 35 Adenosine receptors have been located in a variety of tissues and cells, including hippocampus, adipocytes,

SUBSTITUTE SHEET (RULE 26)

atrioventricle node, striatum, platelets, neutrophils, coronary vasculature and olfactory tubercle. [Jacobson, K.A., Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential. J Med Chem, 1992; 35:407-422.]

Ligands which bind to the adenosine receptor, thereby generating a physiological response which mimics the response caused by the adenosine receptor binding adenosine, are termed adenosine receptor agonists. 10 Likewise, ligands which bind to the adenosine receptor causing the inhibition of the adenosine receptor physiological response are termed adenosine receptor antagonists. Several agonists and antagonists to the A1 and A2 adenosine receptors have been identified; some of 15 these compounds are listed in Table 1.

Preferably, stimulation or activation of the A3 adenosine receptor occurs exclusive of stimulation or activation of the A1 and A2 adenosine receptors. Since 20 identification of ligands which can selectively stimulate or activate the A3 adenosine receptor is an important aspect of the present invention, methods for screening compounds to determine the beneficial preconditioning effects from selectively stimulating the A3 adenosine receptor are provided as described in Example 1 given 25 below. As used herein, useful agonists to the adenosine A3 receptor will have a selectivity for the A3 receptor relative A1 and/or A2 receptors of at least 10:1 and preferably of about 100:1. The ratio may be determined by 30 relative binding potencies at the A1, A2 and A3 adenosine receptor binding sites using methods known in the art. Currently several potent and selective agonists of the A3 receptor are known. These include but are not limited to 35 N⁶-2-(4-amino-3-iodophenyl)ethyladenosine (APNEA), R-phenyl-isopropyladenosine (R-PIA), N⁶-benzyladenosine-5'-N-ethyluronamide, 5'-N-ethylcarboxamidoadenosine (NECA), N⁶-benzyladenosine-5'-N-methyluronamide, N⁶-(3-bromobenzyl)adenosine-5'-N-methyluronamide, N⁶-(3-

iodobenzyl)adenosine-5'-N-methyluronamide, and N⁶-(3-chlorobenzyl)adenosine-5'-N-methyluronamide. Other potent and selective A3 receptor agonists fall within the scope of the present invention.

5 Utility

The methods for protecting tissues and organs from ischemic damage of the present invention may be used in the treatment of a variety of human clinical situations. In particular, these compounds may be used in treating 10 cardiovascular disorders in which injury or dysfunction is caused by ischemia and/or reperfusion (following a period of ischemia). These injuries or dysfunctions include but are not limited to (1) heart attack, a situation that arises from obstruction of one or more of the coronary 15 arteries supplying blood to the heart muscle, and which, if prolonged, leads to irreversible tissue damage; (2) angina pectoris, a clinical condition in which the blood supply to the heart is sufficient to meet the normal needs of the heart but insufficient when the needs of the heart 20 increase (e.g. during exercise), and/or when the blood supply becomes more limited (e.g. during coronary artery spasm); (3) unstable angina associated with pain at rest; and (4) silent ischemia. Thus, a patient with acute 25 myocardial infarction (undergoing a heart attack) would benefit from administration of an agent which activates the A3 adenosine receptor, thus limiting the amount of tissue damage. Likewise, patients undergoing procedures to re-open a blocked vessel, including thrombolysis, 30 percutaneous transluminal coronary angioplasty (PTCA) or atherectomy procedures, also would benefit from treatment with the present invention to limit the deleterious effects of reperfusion. Further, patients with transient ischemic attacks or strokes who are treated with thrombolysis or carotid endarterectomy would benefit from 35 treatment with the present invention as would patients undergoing revascularization procedures or thrombolysis to

resolve stenotic lesions of renal arteries to alleviate hypertension and renal dysfunction.

In advanced coronary artery disease or persistent chest pain at rest, a number of clinical procedures are 5 currently used to improve blood supply to the heart. These include percutaneous transluminal coronary angioplasty (PTCA), percutaneous transluminal directional coronary atherectomy, laser atherectomy, intravascular stents and coronary artery bypass graft surgery. The 10 methods and compounds of this invention will also be useful as adjunctive therapies to these techniques. Other clinical settings that involve ischemia would also be ameliorated by agents which improve ischemic tolerance including organ transplantation, skin flap grafting and 15 other reconstructive surgery, peripheral vascular disease, sepsis, endotoxemia, hemorrhagic shock, pulmonary emboli, pulmonary injury secondary to burns (thermal injury) or septicemia, pulmonary hypertension, microembolization, glomerulonephritis or progressive glomerulosclerosis, 20 atherosclerosis, myocarditis, vasculitis, cardiomyopathies, intestinal ischemia, peripheral vascular disease, transient ischemic attacks, stroke, head trauma and cardiopulmonary arrest.

As can be easily seen, methods for selectively 25 activating the adenosine A3 receptor find widespread clinical utility without the side effects of other treatments. We have demonstrated that tissue may be protected from ischemic damage by activation of the adenosine A3 receptor as indicated in Example 1 in 30 isolated rabbit hearts and in Example 2 in intact rabbits. Example 3 indicates that the preconditioning cardio-protective effect previously thought to be mediated by the A1 receptor is indeed mediated by activation of the A3 receptor. Example 4 describes the dose-response effect 35 of activation of the A3 receptor by the agonist APNEA and shows a significant reduction of infarct size by this method of treatment. Finally Example 5 describes the

SUBSTITUTE SHEET (RULE 26)

applicants' A3 receptor binding assay. This method involves the use of the human A3 receptors which are the subject of pending U.S. patent application 08/070,689 which is incorporated herein by reference. The results of 5 this A3 binding assay may be compared to the results of A1 and A2 binding assays known in the art to determine the selectivity and potency of potential A3 receptor agonists. Other situations in which the method of the present invention would find utility are known to those skilled in 10 the art and are not limited to those described above.

Formulations

Compounds of the invention are administered to the affected tissue at the rate of from 0.1 to 100 nmol/min/kg, preferably from 1 to 20 nmol/min/kg. Such rates are 15 easily maintained when these compounds are intravenously administered as discussed below. When other methods are used (e.g., oral administration), use of time-release preparations to control the rate of release of the active ingredient may be preferred. These compounds are given in 20 a dose of about 0.2 mg/kg/day to about 50 mg/kg/day, preferably from about 0.5 mg/kg/day to about 10 mg/kg/day, preferably given in intermittent periods, preferably with each period of treatment being 24 hours or less in order to avoid down regulation or tolerance.

25 For the purposes of this invention, the compounds may be administered by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as 30 used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection including perfusion, for example during CABG surgery, as used herein includes administration through 35 catheters. Preferred for certain indications are methods of administration which allow rapid access to the tissue

or organ being treated, such as intravenous injections for the treatment of myocardial infarction. When an organ outside a body is being treated, perfusion is preferred.

Pharmaceutical compositions containing the active 5 ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. 10 Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and 15 preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, 20 inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, 25 stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastro-intestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material 30 such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate 35 or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethyl-cellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservative such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agent, one or more flavoring agent and one or more sweetening agent, such as sucrose or saccharin.

Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example

sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily 5 phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as 10 soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain 15 sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.

20 The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and 25 suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol or prepared as a lyophilized 30 powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In 35 addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.

The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release 5 formulation intended for oral administration to humans may contain 20 to 200 μ moles of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total composition. It is preferred that pharmaceutical 10 composition be prepared which provides easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion should contain from about 20 to about 50 μ moles of the active ingredient per milliliter of solution in order that infusion of a 15 suitable volume at a rate of about 30 mL/hr can occur.

As noted above, formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; 20 as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.

25 A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free flowing form such as a powder or granules, optionally mixed with 30 a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface active or dispersing agent. Molded tablets may be 35 made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be

formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be 5 provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous with the compounds susceptible to acid hydrolysis.

Formulations suitable for topical administration in 10 the mouth include lozenges comprising the active ingredient in a flavored basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active 15 ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for vaginal administration may 20 be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration 25 include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may 30 include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be sorted in a freezedried (lyophilized) condition requiring only the addition of the sterile liquid carrier, 35 for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions

may be prepared from sterile powders, granules and tablets of the kind previously described.

Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an 5 appropriate fraction thereof, of an adenosine A3 receptor agonist compound.

It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific 10 compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as 15 is well understood by those skilled in the art.

The method may be used following thrombolysis for coronary occlusion. The compound would be given as a sterile injectable preparation with water or isotonic sodium chloride as the solvent. The solution can be 20 administered intravenously or directly into the coronary artery at the time of left heart catheterization or into a carotid artery. The rate of administration could vary from 1 to 20 nmole/min/kg with, for example, an infusion volume of 30 ml/hr. Duration of therapy would typically 25 be about 96 hours.

Angina and early myocardial infarcts can be treated by intravenous administration using a sterile injectable preparation using the rates discussed above.

Capsules comprising adenosine A3 agonists suitable 30 for oral administration according to the methods of the present invention may be prepared as follows: (1) for a 10,000 capsule preparation: 1500 g of adenosine A3 receptor agonist is blended with other ingredients (as described above) and filled into capsules which are 35 suitable for administration depending on dose, from about 1 capsule per day to about 8 capsules per day (2 capsules per 6 hours), to an adult human.

The following examples are illustrative of the invention but they should not however be construed as specifically limiting the scope of the invention and variations of the invention, now known or later developed, 5 are considered to fall within the scope of the present invention as herein after claimed.

Example 1: Comparison of the Reduction of Infarct Size in Preconditioned Rabbits and Rabbits Treated with A₂ Agonist

The following example compares infarct size and 10 hemodynamic values in groups of rabbits who have been preconditioned or who were treated with a variety of adenosinergic agents. Further, the effect on hemodynamic parameters was measured in a separate group of animals in which ischemia was not induced to verify that these agents 15 were physiological active at the doses employed.

Chemicals

Adenosine (ADO) was obtained from Sigma. 8-(p-Sulfophenyl)-theophylline (SPT) and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) were purchased from Research 20 Biochemicals Inc., Natick, MA. N⁶-2-(4-amino-3-iodophenyl)ethyladenosine (APNEA) was provided by Dr. Ray A. Olsson, Department of Internal Medicine, the University of South Florida, Tampa, Florida. ADO, CCPA and SPT were mixed with 1.0 ml of distilled water while DPCPX and APNEA 25 were solubilized in ethanol and DMSO, respectively. These solutions were then diluted in Krebs buffer to the final concentration just before the experiments started.

Surgical Preparation of the Animals

New Zealand white rabbits of either sex, between 1.4-30 2.4 kg, were anesthetized with intravenous sodium pentobarbital (30 mg/kg). The neck was opened and a tracheotomy was performed. The rabbits were ventilated with 100% oxygen via a positive pressure respirator (MD industries, Mobile, Alabama). Ventilation rate was 30-35 35 breaths per minute, and tidal volume was approximately 15 ml. A left thoracotomy was performed in the fourth

SUBSTITUTE SHEET (RULE 26)

intercostal space and pericardium was opened to expose the heart. A 2-0 silk suture with an RB taper needle was passed around a branch of the left coronary artery, and the end of the silk were threaded through a small vinyl tube to form a snare. The hearts were quickly excised and mounted on a Langendorff apparatus and perfused at constant pressure with Krebs buffer containing (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO₄, 1.2 K₂PO₄, 24.3 NaHCO₃, 2.5 CaCl₂ and 10 glucose. The Krebs buffer was gassed with 95% O₂ plus 5% CO₂ which resulted in a pH of 7.4-7.5 and pO₂ of 500-600 mm Hg. The temperature of the perfusate was maintained at 37 °C. The perfusion pressure was kept at 75 mm Hg. Pacing electrodes were placed on the right atrium and all hearts were paced at 200 beats/minute with pulses of 5 volts and 4 msec duration to keep the heart rate constant. A fluid-filled latex balloon connected to a transducer via PE240 tubing was inserted into the left ventricle. Balloon volume was adjusted to set the left ventricular diastolic pressure at 10 mm Hg at the beginning of the experiment. Total coronary artery flow was measured by timed collection of buffer from the chamber into a graduated cylinder. Regional ischemia was effected by pulling the snare tight and clamping the tube with a hemostat. Global ischemia was performed by clamping the inflow tubing of the Langendorff apparatus. Reperfusion was achieved by releasing the restriction. All hearts were allowed to equilibrate for 20 minutes before the experiments were started. Heart rate (HR), coronary flow (CF) and left ventricular developed pressure (LVDP) were recorded at the point just before and at the end of each treatment with the pacing momentarily turned off.

Measurement of Infarct and Risk Area

At the end of each experiment, the silk suture under the coronary branch was tightly tied to occlude the artery, and a 0.5% suspension of fluorescent particles (1-

10 μ m diameter from Duke Scientific Corp., Palo Alto, CA) were infused into the perfusate to mark the risk zone as the non-fluorescent tissue. The hearts were removed from the Langendorff apparatus, weighed and then frozen. The 5 hearts were cut into 2 mm transverse slices. The slices were thawed and incubated in 1% triphenyl tetrazolium chloride (TTC) in pH 7.4 buffer for 20 minutes at 37 °C. TTC reacts with NADH and dehydrogenase enzymes and stains all tissue still having them to a deep red color. The 10 infarcted area of the heart loses those constituents and does not stain. After staining, the area of infarcted tissue (TTC negative tissue) and the risk zone (area lacking fluorescence under ultraviolet light) in each slice were traced. The area of infarct and risk zone were 15 determined by planimetry of the tracing. The volume of infarcted myocardium and myocardium at risk was then calculated by multiplying the planimetered areas by the slice thickness.

Experimental Protocols

20 The animals were divided into 10 groups. The basic protocol is shown in Figure 1. The hearts in all groups were subjected to a 30 minutes coronary branch occlusion followed by 120 minutes reperfusion. Control group (CON, n=10) only experienced the above-mentioned 30 minutes of 25 regional ischemia while the preconditioned group (PC, n=12) received an additional 5 minutes of global ischemia plus 10 minutes of reperfusion prior to the 30 minute occlusion. In the adenosine group (ADO, n=6) and the APNEA group (APNEA, n = 5), the hearts were exposed to 10 30 μ M adenosine and 50 nM APNEA respectively, for 5 minutes as a substitute for ischemic preconditioning. The drug was allowed to washout for 10 minutes before the 30 minute ischemia was started. In groups receiving SPT, the blocker was included in the perfusate for 15 minutes at 35 100 μ M starting 5 minutes before the exposure of ADO (ADO-SPT group, n=6) or APNEA (APNEA-SPT group, n=5) or 5

minutes before and after 5 minutes of preconditioning ischemia (PC-SPT group, n=5). Groups ADO-DPCPX (n=6), APNEA-DPCPX (n=4) and PC-DPCPX (n=5) were identical to three SPT groups except that 200 nM DPCPX was substituted 5 for the SPT.

Statistics

All results are expressed as group mean \pm SEM. The differences among groups was determined by a one-way analysis of variance with a Newman-Keuls post hoc test. 10 A value of p<0.05 was considered to be significant.

Data were contributed from 73 rabbits. No heart which was not perfused with buffer within one minute after excision or whose developed pressure was less than 80 mm Hg after equilibration was used in the present study.

15 Measurement of Effect of Agents on Hemodynamic Responses

In order to ensure that the adenosinergic agents were active at the concentrations employed, hemodynamic responses were measured in a separate group of animals who experienced similar surgery described above except the 20 coronary snare was not installed. The hearts were quickly excised and mounted on the Langendorff apparatus and perfused with Krebs buffer. The depressant effect of adenosine on atrioventricular (AV) conduction time was measured at a constant rate of atrial pacing. A constant 25 pacing atrial cycle length is necessary because AV conduction is modulated by atrial rate, which in turn is affected by adenosine. The hearts were electrically paced at an atrial cycle length of 300 ms (4 Hz, pulse duration of 2 ms) via bipolar electrode placed on the right atrium. 30 Measurements of AV conduction time were made by a bipolar extracellular electrode on the surface of the hearts which then were connected with the EKG recorded. Stimulus-to-ventricle (S-R) interval was used from EKG as the measure of AV conduction. Coronary flow was measured with a 35 flowmeter (BL-622, Biotronex). All drugs were infused

into the perfusion line at various flow rates via a syringe pump to achieve the desired perfusate concentrations.

Discussion of Results

5 Figure 2 summarizes the hemodynamic data for all groups, Heart rate (HR), coronary flow (CF) or left ventricular developed pressure (LVDP) at pretreatment from all groups was similar. Treatment with SPT or DPCPX alone only slightly affected hemodynamics in the hearts.

10 However, infusing ADO (10 μ M) for 5 minutes significantly decreased the HR from 176 ± 8 beats/min to 149 ± 6 beats/minutes and increased CF from 7.6 ± 0.6 ml/g/min to 10.3 ± 0.8 ml/g/min via A_1 and A_2 receptors, respectively. Those effects completely disappeared during the 10 minutes

15 of washout. Both the HR decrease (A_1 effect) and CF increase (A_2 effect) from ADO infusion could be abolished by SPT (100 μ M), non-selective antagonist. The highly selective A_1 antagonist-DPCPX (200 nM) only eliminated the decrease in HR but did not affect the increase of CF.

20 APNEA (50 nM), a highly selective A_3 receptor agonist, did not significantly alter HR, CF or LVDP at this dose.

Infarct size data are shown in Figure 3. There was no significant difference in the area at risk for all groups. Infarct size was normalized and expressed as 25 percentage of the area at risk infarcted. In the isolated rabbit hearts, 30 minutes of coronary branch occlusion caused $29.4 \pm 2.9\%$ of risk zone to be infarcted in control hearts while only $10.8 \pm 2.8\%$ in preconditioned hearts ($p<0.01$). PC (preconditioning) protected the hearts from 30 infarction as well as in previous *in situ* rabbits. Exposure to ether ADO (10 μ M) or APNEA (50 nM) for 5 minutes also protected the hearts ($11.4 \pm 2.1\%$ and $11.9 \pm 2.3\%$, respectively). Infarct sizes in the ADO and APNEA groups were not different from those in the preconditioned 35 group and significantly smaller than those in the control group ($p<0.01$) (Fig. 2). In the present study, however,

SPT (non-selective adenosine antagonist) completely blocked protection against myocardial infarction from either PC ($33.8 \pm 2.4\%$), exposure to ADO ($29.8 \pm 3.4\%$) or APNEA ($32.8 \pm 3.3\%$). DPCPX is a highly A₁-selective and 5 powerful adenosine receptor blocker. We found that DPCPX (200 nM) entirely blocked adenosine's effect on heart rate. However, in terms of the infarct size, DPCPX failed to prevent the protection against infarction afforded by the infusion of either 10 uM ADO ($14.4 \pm 7.0\%$). (The 10 infarct size in the three DPCPX groups (PC-DPCPX, ADO-DPCPX and APNEA-DPCPX) was not significantly different from the groups without DPCPX (PC, ADO and APNEA) (Fig. 4).

Based upon the results presented, applicants have now 15 demonstrated that isolated buffer perfused rabbit hearts can be protected against infarction by ischemic preconditioning. The advantage of the isolated buffer perfused heart model is that it allows the delivery of drugs to the heart at a known dose and schedule. Studies with this 20 model have led us to propose that preconditioning is mediated by the A₃ adenosine receptor rather than the A₁ as was previously thought.

These results indicate that neither the A₁ nor A₂ adenosine receptors are activated with 50 nM APNEA. 25 Further, use of the A₁-selection antagonist DPCPX (200 nM) completely blocked the reduction of heart rate, which is an A₁ receptor mediated effect, but did not block the beneficial effects of APNEA.

Receptor binding studies reveal that the A₃ receptor 30 can be stimulated by APNEA. Other A₁ agonists, such as R-PIA, which also have high affinity for the A₃ receptor are employed to selectively stimulate the A₃ receptors, and preferably an A₁ antagonist is also administered to block A₁ receptor mediated effects.

Example 2:The A₁-receptor mediates the cardioprotective effect of I-APNEA in the intact rabbit.

The previous studies have demonstrated that the 5 cardioprotective effects of APNEA in isolated rabbit hearts is not prevented by the selective A₁-receptor antagonist, DPCPX. No studies have demonstrated the same result in the intact, blood perfused heart. In this study, the effect of the adenosine receptor agonist, I-10 APNEA, on infarct size in the anesthetized rabbit was compared to the protection observed with ischemic preconditioning (PC).

New Zealand White rabbits (1.5-2.5 kg) were anaesthetized with pentobarbital sodium (40 mg/kg) 15 administered via a catheter in a marginal ear vein. The animals were intubated with a pediatric cuffed endotracheal tube and ventilated with room air using a positive pressure respirator (Harvard Apparatus, Natick, Mass.). The heart was exposed *in situ* via an incision 20 between the left 4th and 5th ribs, and a branch of the left coronary artery was isolated, using a 3-0 silk suture on RB-taper needle, for later ligation to induce 30 minutes of ischemia followed by 180 minutes of reperfusion. A catheter inserted into a femoral vein was 25 used for administration of fluids and drugs. Infarct size was measured using the method described in the section entitled "Measurement of Infarct Size and Risk Area" in Example 1.

All animals received 30 minutes of regional 30 ischemia, induced by tightening the suture placed around the coronary artery. Following the 30 minutes of ischemia, the suture was loosened, and reperfusion was allowed for the ensuing 180 minutes. Control animals received only the 30 minutes of ischemia and 180 minutes 35 of reperfusion (n=9). Ischemic preconditioning (PC) was induced by 5 minutes occlusion of the coronary artery followed by 10 minutes reperfusion before the 30 minutes

occlusion (n=7). In a separate group of rabbits, I-APNEA was delivered intravenously as a slow bolus injection (.25 mg/kg), beginning 15 minutes prior to the 30 minutes occlusion (n=8). In two additional groups of rabbits, the 5 effects of the A₁-selective adenosine receptor blocker, DPCPX, were tested against the effects of PC (n=6) and I-APNEA (n=8). In these animals, DPCPX was administered as a slow bolus (5 minutes) injection (0.5 mg/kg, iv.), ending 5 minutes prior to either the PC ischemia or the 10 injection of I-APNEA. At the end of 120 minutes of reperfusion, all animals were killed by an overdose of pentobarbital, and risk area and infarct size were measured.

In untreated control rabbits, infarct size was 15 52±4.3%. The infarct size was reduced to 9±4.1% by PC. I-APNEA reduced the infarct size to 17±3.8%. Pretreatment with the selective A₁- receptor antagonist, DPCPX (0.5 mg/kg, IV), did not affect the reduction in infarct size with PC (7±1.8%) or I-APNEA (28±8.0%). DPCPX did abolish 20 the bradycardia and attenuated the fall in mean arterial pressure observed with administration of either I-APNEA (0.25 mg/kg) or the selective A₁-receptor agonist, R-phenylisopropyladenosine (R-PIA, 1 mg/kg, iv.).

These results show that PC and I-APNEA reduce 25 infarct size in anaesthetized rabbits by a non-A₁ receptor dependent mechanism, and support the conclusion that activation of A₃ receptors confers cardioprotection in intact, blood perfused rabbit hearts.

Example 3: Adenosine A₃ - Receptor Mediation of
30 Preconditioning in Rabbit Heart.

The methods utilized in this example are identical to those described in Example 1. All hearts received 30 minutes of regional ischemia as described in Example 1. The control group (n= 8) hearts received only 30 minutes 35 of ischemia. Preconditioned (PC) hearts (n= 10) received 5 minutes of global ischemia and 10 minutes of reperfusion

prior to the regional ischemia. Adenosine (ADO) treated hearts (n= 6) received 10 μ M adenosine for 5 minutes prior to regional ischemia. APNEA treated hearts (n= 6) received 65 μ M APNEA for 5 minutes prior to regional ischemia. In groups receiving the nonselective adenosine blocker, 8-SPT, the blocker was included in the perfusate for 15 minutes at 100 μ M starting 5 minutes before the exposure of ADO (ADO-SPT group, n= 6), or APNEA (APNEA-SPT group, n= 6) or 5 minutes before and after 5 minutes of preconditioning ischemia (PC-SPT group, n= 5). The methods for groups ADO-DPCPX, (n= 6), APNEA-DPCPX (n= 6), and PC-DPCPX (n= 5) were identical to the three SPT groups except that 200 nM DPCPX was substituted for the SPT. For the PC-BW group (n= 5), the A_3 -receptor antagonist, BW 15 A1433, [Linden J, et al., Molecular Pharmacology 44:524-532 (1993)], was administered at a dose of 200 nM in the perfusate for 5 minutes before and 5 minutes after PC ischemia.

Infarct size in control, untreated hearts averaged 20 32.2 \pm 1.5% of the risk area. PC with 5 minutes global ischemia and 10 minutes reperfusion prior to 30 minutes ischemia reduced infarct size to 8.8 \pm 2.3%. ADO and APNEA reduced infarct size to 11.4 \pm 2.3% and 12.6 \pm 2.2%, respectively. The non-selective adenosine receptor 25 antagonist, 8-SPT, prevented the protection with PC (33.8 \pm 2.7%), ADO (29.8 \pm 3.7%) and APNEA (30.3 \pm 3.3%), but DPCPX, the selective A_1 -receptor antagonist, did not prevent the effects of the three interventions (15.6 \pm 7.8%, 14.4 \pm 2.8%, and 8.7 \pm 1.7%, respectively). 30 However, BW A1433, a potent A_3 -receptor antagonist, completely blocked the protective effect of PC (26.2 \pm 3.2%).

The results with DPCPX suggest that cardioprotection with PC, ADO and APNEA is mediated via a non- A_1 receptor 35 mechanism. The results with BW A1433 suggest that the cardioprotection observed with PC in the rabbit heart is mediated by the A_3 -receptor.

Example 4: Dose-response to the adenosine receptor agonist, APNEA, on infarct size in isolated rabbit hearts.

In this study, applicants examined the effects of varying dosage of APNEA on myocardial infarct size in 5 Langendorff buffer-perfused rabbit hearts subject to 30 minutes of regional ischemia and 2 hours reperfusion. The methods utilized in this example are identical to those described in Example 1.

Six groups of hearts were studied: control untreated 10 hearts (n=10); APNEA 0.5 nM (n=6); APNEA 5 nM (n=6); APNEA 50 nM (n=6); APNEA 500 nM (n=6); and APNEA 500 nM + DPCPX 200 nM. In all cases, APNEA (0.5-500 nM) was infused for 5 minutes, beginning 15 minutes prior to 30 minutes of ischemia. The regional ischemia was produced by occlusion 15 of the coronary artery, followed by 120 minutes reperfusion. The results are shown below in Table A. The results are shown below in Table A.

Table A

			Risk Area (% of LV)	Infarct Area (% of Risk)
20	<u>Treatment</u>	<u>n</u>		
Control	10	44 ± 3	24 ± 1	
APNEA .5 nM	6	45 ± 5	22 ± 5	
APNEA 5 nM	6	57 ± 3	14 ± 3*	
APNEA 50 nM	6	52 ± 5	14 ± 3*	
25	APNEA 500 nM	6	45 ± 2	8 ± 1*
	APNEA ± DPCPX	6	53 ± 5	15 ± 5*

At doses of 5, 50, and 500 nM, APNEA reduced infarct size, an effect which was not blocked by DPCPX. However, at a dose of 0.5 nM, APNEA had no effect on infarct size 30 when compared to untreated control hearts.

In an additional group of 3 hearts that were not made ischemic, 500 nM APNEA was infused for 1 minute. This group of hearts was not paced to control heart rate, and the effects of APNEA on spontaneous heart rate and 35 coronary flow were measured to determine the hemodynamic effects of APNEA.

APNEA (500 nM) had no effect on heart rate or coronary flow in non-ischemic hearts. In the three hearts studied, heart rate was 178 ± 7 and 169 ± 3 beats/min before and after APNEA, respectively. Coronary flow was 5 50 ± 9 and 58 ± 6 ml/min before and after APNEA, respectively.

These results show that APNEA reduces infarct size at doses of 5 nM and above, but that 0.5 nM APNEA is ineffective in reducing infarct size. The results further show 10 that the reduction in infarct size with APNEA is mediated by a non- A_1 -adenosine receptor and the stimulation of the A_3 -receptor with APNEA results in no hemodynamic effects on coronary flow or heart rate.

Example 5: A_3 Adenosine Receptor Binding Assay

15 Chinese hamster ovary (CHO) cells, obtained from ATCC, expressing the cloned human A_3 adenosine receptor [for example, 5L cells or a mutagenized A_3 adenosine receptor (e.g., A3K2)] were grown under standard cell culture conditions and harvested by mechanical agitation 20 in cell culture medium. All further procedures were carried out at 4 °C. The cells were disrupted using a Polytron and the resulting cell membranes collected by centrifugation at 50,000 g for 20 minutes. The pellet was suspended in 10 mM Tris-HCl buffer, pH 7.4, (10^6 cells/mL) 25 using the Polytron and centrifuged at 50,000 g for 20 minutes. The resulting pellet was resuspended in 10 mM Tris-HCl buffer, pH 7.4, using the Polytron and centrifuged at 50,000 g for 20 minutes. The pellet was resuspended in 10 mM Tris-HCl buffer, pH 7.4 (10^6 30 cells/ $20\mu\text{L}$). A sample of the membrane suspension was taken for determination of the protein content by the method of Lowry, et al., (J. Biol. Chem. 193: 265-275, 1951).

For the binding assay, 50 μg of membrane protein were 35 incubated with 0.4 nM [^{125}I]-aminobenzyladenosine (ABA, custom synthesized by DuPont:NEN; specific activity = 2200

Ci/mmol) in 50 mM Tris-HCl buffer, pH 7.4, containing 5 mM MgCl₂ and 1 unit/mL adenosine deaminase in a total volume of 100 μ L for 2 hours at room temperature. Membranes containing bound radioactivity were collected on Whatman 5 GF/B filters using a Brandel Cell Harvester and washed 3 times with ice-cold 50 mM Tris-HCl buffer, pH 7.4. Radioactivity was quantified using a Beckman gamma counter. To determine receptor-bound radioactivity (specific binding), a parallel set of tubes containing 10 10 μ M I-ABA, in addition to all other assay ingredients, was prepared in which radioactive bound non-specifically to the membranes was measured. The specific binding was then calculated by subtracting this non-specific binding value from the total binding.

15 The specific binding of [¹²⁵I]ABA to the cell membranes of the A3K2 line was displaced by I-ABA in a concentration-dependent manner, with an IC₅₀ of 2 nM (Figure 5). This indicates that the radiolabel binds to human A3 receptors expressed in these cells with high 20 affinity.

Table 1 Some A₁ and A₂ receptor agonists and antagonists

Abbreviation	Chemical Name
<u>A₁ agonists</u>	
5 R-PIA	(R)-N-(2-phenyl-1-methylethyl)adenosine
CPA	N ⁶ -cyclopentyladenosine
CHA	N ⁶ -cyclohexyladenosine
CCPA	2-chloro-N ⁶ -cyclopentyladenosine
5-ENBA	N ⁶ -endo-norborn-2-yladenosine
10 APNEA	N6-2-(4-amino-3-iodophenyl)ethyladenosine
ABA	N ⁶ -(4-amino-3-iodobenzyl)adenosine
<u>A₁ antagonists</u>	
DPCPX	1,3-dipropyl-8-cyclopentylxanthine
XAC	8-(4-[(2-aminoethyl)amino]carbonyl)oxy-phenyl}-1,3-dipropylxanthine
15 BW-A844u	1-propyl-3-(4-amino-3-iodophenylethyl)-8-cyclopentylxanthine
N-0861	N ⁶ -butyl-8-phenyladenine
KFM 19	(±)-8-(3-oxocyclopentyl)-1,3-dipropylxanthine
BW-A844U	1-propyl-3-[2-(4-amino-3-iodophenyl)ethyl]-8-cyclopentylxanthine
KF 15372	1,3-dipropyl-8-(dicyclopropylmethyl)xanthine

A₂ agonists

CGS 21680	2- [4 - (2-carboxylethyl) phenyl] ethylamino- 5'-N-ethylcarboxamidoadenosine
CGS 22492	2- [(cyclohexylethyl) amino] adenosine
CGS 22989	2- [(cyclohexenyl)] amino] adenosine
5 CHEA	2- (2-cyclohexylethoxy) adenosine

A₂ antagonists

DATSX	1,3-diallyl-8- (3,4,5-trimethoxystyryl) - 7-methylxanthine
DM TSX	8- (3,4,5-trimethoxystyryl) -1,3,7-tri- methylxanthine

Claims

1. A method for preconditioning an organ to protect the organ from ischemic damage comprising administering an agonist to the A3 adenosine receptor.

5 2. A method as in claim 1 wherein the organ is the heart.

3. A method as in claim 2 wherein the agonist to the A3 adenosine receptor is administered by perfusing the heart during surgery.

10 4. A method of claim 2 wherein the agonist is administered intravenously before and during the surgery.

5. A method as in claim 1 wherein the agonist to the A3 adenosine receptor is selected from the group consisting of N⁶-2-(4-amino-3-iodophenyl)ethyladenosine
15 (APNEA), R-phenylisopropyladenosine (R-PIA), 5'-N-ethylcarboxamidoadenosine (NECA), N⁶-benzyladenosine-5'-N-methyluronamide, N⁶-(3-bromobenzyl)adenosine-5'-N-methyluronamide, N⁶-(3-iodobenzyl)adenosine-5'-N-methyluronamide, and N⁶-(3-chlorobenzyl)adenosine-5'-N-
20 methyluronamide.

6. A method as in claim 1 further comprising the step of administering an antagonist to the A1 adenosine receptor.

7. A method as in claim 5 wherein the antagonist to the A1 adenosine receptor is selected from the group consisting of DPCPX and XAC.
25

8. A method for preventing ischemic damage to an organ comprising administering an agonist to the A3 adenosine receptor.

SUBSTITUTE SHEET (RULE 26)

9. A method as in claim 8 wherein the organ is the heart.

10. A method as in claim 8 wherein the organ is the brain.

5 11. A method for treating ischemic damage to an organ comprising administering an agonist to the A3 adenosine receptor.

12. A method as in claim 11 wherein the organ is the heart.

10 13. A method as in claim 11 wherein the organ is the brain.

14. A method for protecting an organ from damage comprising the steps of:

15 administering an antagonist to the A1 adenosine receptor; and

administering an agonist to the A3 adenosine receptor.

15. A method as in claim 14 wherein the organ is the heart.

20 16. A method as in claim 14 wherein the antagonist to the A1 adenosine receptor is DPCPX.

17. A method as in claim 14 wherein the agonist to the A3 adenosine receptor is selected from the group consisting of N⁶-2-(4-amino-3-iodophenyl)ethyladenosine (APNEA), R-phenyl-isopropyladenosine (R-PIA), 5'-N-ethylcarboxamidoadenosine (NECA), N⁶-benzyladenosine-5'-N-methyluronamide, N6-(3-bromobenzyl)adenosine-5'-N-methyluronamide, N⁶-(3-iodobenzyl)adenosine-5'-N-

methyluronamide, and N⁶- (3-chlorobenzyl) adenosine-5' -N-methyluronamide.

18. A method as in claim 14 wherein the APNEA and DPCPX are administered by intravenous or intracoronary 5 infusion.

19. A method of claim 16 wherein a therapeutically effective amount of DPCPX is administered to the heart.

20. A method of claim 17 wherein a therapeutically effective amount of APNEA is administered to the heart.

10 21. A method for mediating the ischemic preconditioning of the heart comprising stimulating the A3 adenosine receptors.

15 22. A method according to claim 21 wherein the A3 adenosine receptors are stimulated by administering an A3 agonist selected from the group consisting of APNEA and R-PIA.

20 23. A method for prevention of tissue injury induced by ischemic-reperfusion comprising the steps of:
administering an adenosine receptor agonist;
administering an A1 adenosine receptor antagonist; and
administering an A2 adenosine receptor antagonist.

25 24. A method according to claim 23 wherein the adenosine receptor agonist is selected from the group consisting of NECA and adenosine.

25. A method according to claim 23 wherein the A1 adenosine receptor antagonist is selected from the group

consisting of DPCPX, XAC, BW-A844u, N-0861, KF 15372, and KFM 19.

26. A method according to claim 23 wherein the A2 adenosine receptor antagonist is selected from the group 5 consisting of DATSX and DM TSX.

27. A method according to claim 1 wherein the agonist to the A3 adenosine receptor has a selectivity for the A3 receptor compared to the A1 and A2 receptors of at least about 10:1.

10 28. A method according to claim 1 wherein the agonist to the A3 adenosine receptor has a selectivity for the A3 receptor compared to the A1 and A2 receptors of at least 100:1.

15 29. A method of claim 1 wherein the agonist is administered prophylactically.

30. A method of claim 1 wherein the agonist is administered intravenously.

31. A method of claim 1 wherein the agonist is administered orally.

20 32. A method of claim 1 wherein the agonist is administered intermittently.

25 33. A method for preconditioning an organ of a patient at risk to protect the organ from ischemic damage comprising administering an agonist to the A3 adenosine receptor.

34. A method of claim 1 wherein administration of the agonist does not cause heart block or bradycardia.


SUBSTITUTE SHEET (RULE 26)

35. A method of claim 1 wherein administration of the agonist does not cause significant hypotension.

SUBSTITUTE SHEET (RULE 26)

1/4

FIG. 1.



INFUSION OF SPT OR DPCPX



TREATMENT WITH:

- 1). GLOBAL ISCHEMIA
- 2). ADO (10 μ M)
- 3). APNEA (50 nM)

SUBSTITUTE SHEET (RULE 26)






FIG. 2.



3/4


FIG. 4.



SUBSTITUTE SHEET (RULE 26)

4/4

FIG. 5.



* $p < 0.05$ vs. Vehicle: ANOVA with Scheffe's post-hoc test

$p < 0.0005$ vs. Vehicle: AVOVA with Scheffe's post-hoc test

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/02854

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61F 2/02; A61K 9/14, 9/20, 9/48; A61M 31/00
US CL : 424/423, 451, 464, 489; 514/937; 604/51

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/423, 451, 464, 489; 514/937; 604/51

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 89 (16), 1992, (ZHOU ET AL.), "MOLECULAR CLONING AND CHARACTERIZATION OF AN ADENOSINE RECEPTOR: THE A3 ADENOSINE RECEPTOR", ABSTRACT ONLY.	1-35

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents:	
•A" document defining the general state of the art which is not considered to be part of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
•P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 APRIL 1994

Date of mailing of the international search report

12 MAY 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT

Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

THURMAN K. PAGE

Telephone No. (703) 305-2351

Form PCT/ISA/210 (second sheet)(July 1992)★

THIS PAGE BLANK (USPTO)